New Drugs and Expanded Indications
Below are postings for new drugs and indications from our corporate sponsors you should be aware of. Please refer to the links below for announcements and details. To view a full list of approvals, please visit www.fda.gov.
To view current and resolved drug shortages and discontinuations reported to FDA click here.
09/27/2023
FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
Therapies
Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!